Original Article

Comparison of Different Risk Factors that Result in Endothelial Damage Leading to Diabetic Microangiopathy

Authors: Seyit Mehmet Kayacan, MD, Rümeyza Kazancıoğlu, MD, Hüseyin Oflaz, MD, Şerafettin Tuna, MD

Abstract

In this study, the effect of different risk factors (hyperglycemia, hypertension, hyperlipidemia, hyperuricemia) on endothelial damage was evaluated in 61 (two of them were type 1; the other patients were type 2) diabetic patients. von Willebrand factor antigen was used as the marker of the endothelial damage. Although there was no significant decrease (P > 0.05) in von Willebrand factor level after regulation of nonregulated diabetes, a significant decrease was determined in nonregulated and hypertensive diabetic patients after improvement of risk factors (P < 0.05). As a result, nonregulated diabetes alone has less effect than nonregulated diabetes plus other risk factors (particularly hypertension) on diabetic angiopathy.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

  1. Galajada P, Martinka E, Mokan M, Kubisz P. Endothelial markers in diabetes mellitus. Thromb Res 1997; 85: 63–65.
  2. Glassock RJ, Brenner BM. Glomerulopathies associated with multisystem diseases, in Wilson JD, Braunwald E, Isselbacher KJ, Petersdorf RG, Martin JB, Fauci AS, et al (eds): Harrison's Principles of Internal Medicine. New York, McGraw-Hill Health Professions Division, 1991, ed 12, pp 1180–1186.
  3. Lip GY, Blann A. Von Willebrand factor: A marker of endothelial dysfunction in vascular disorders? Cardiovasc Res 1997; 34: 255–265.
  4. Blann AD, de Romeuf C, Mazurier C, McCollum CN. Circulating von Willebrand factor antigen II in atherosclerosis: A comparison with von Willebrand factor and soluble thrombomodulin. Blood Coagul Fibrinolysis 1998; 9: 261–266.
  5. Ward JD, Baker RWR, Davis BH. Effect of blood sugar control on the accumulation of sorbitol and fructose in nervous tissue. Diabetes 1972; 21: 1173–1178.
  6. Woolf AD, Wakerley G, Wallington TB, Scott DGI, Dieppe PA. Factor VIII related antigen in the assessment of vasculitis. Ann Rheum Dis 1987; 46: 411–447.
  7. Kahaleh MB, Osborn I, LeRoy EC. Increased factor VIII/von Willebrand factor antigen and von Willebrand factor activity in scleroderma and in Raynaud's phenomenon. Ann Intern Med 1981; 94: 482–484.
  8. Coller BS, Frank RN, Milton RC, Gralnick HR. Plasma cofactors of platelet function: Correlation with diabetic retinopathy and hemoglobins A1a–c. Ann Intern Med 1978; 88: 311–316.
  9. Jensen T. Increased plasma concentration of von Willebrand factor in insulin dependent diabetics with incipient nephropathy. BMJ 1989; 298: 27–28.
  10. Jensen T, Knudsen JB, Rasmussen BF, Deckert T. Features of endothelial dysfunction in early diabetic nephropathy. Lancet 1989; 1: 461–463.
  11. Warrell RP, Hultin MB, Coller BS. Increased factor VIII/von Willebrand factor antigen and von Willebrand factor activity in renal failure. Am J Med 1979; 66: 226–228.
  12. Stehouwer CD, Fischer HR, van Kuijk AW, Polak BC, Donker AJ. Endothelial dysfunction precedes development of microalbuminuria in IDDM. Diabetes 1995; 44: 561–564.
  13. Bithell TC. Blood coagulation. In: Lee GR, Bithell TC, Foerster J, Athens JW, Lukens JN, eds. Wintrobe's clinical hematology, 9th ed. 1993, pp. 566–615.
  14. Morise T, Takeuchi Y, Kawano M, Koni I, Takeda R. Increased plasma levels of immunoreactive endothelin and von Willebrand factor in NIDDM patients. Diabetes Care 1995; 18: 87–89.
  15. Porta M, La Selva M, Molinatti PA. von Willebrand factor and endothelial abnormalities in diabetic microangiopathy. Diabetes Care 1991; 14: 167–172.
  16. Ribau JC, Hatton MW, Richardson M. Changes in the aortic endothelium and plasma von Willebrand factor levels during the onset and progression of insulin-dependent diabetes in BB rats. Atherosclerosis 1998; 139: 291–299.
  17. Mauer SM, Miller K, Goetz FC, Barbosa J, Simmons RL, Najarian JS, et al. Immunopathology of renal extracellular membranes in kidneys transplanted into patients with diabetes mellitus. Diabetes 1976; 25: 709–712.
  18. Siperstein MD, Feingold KR, Bannett PH. Hyperglycaemia and diabetic microangiopathy. Diabetologia 1978; 15: 365–367.
  19. Barclay WR. University Group Diabetes Program revisited. JAMA 1978; 240: 377–378(editorial).
  20. Abayomi EA, Miller E, Paton RC. Von Willebrand factor in diabetic retinopathy. Cent Afr J Med 1996; 42: 205–206.
  21. Plater ME, Ford I, Dent MT, Preston FE, Ward JD. Elevated von Willebrand factor antigen predicts deterioration in diabetic peripheral nerve function. Diabetologia 1996; 39: 336–343.
  22. Blann AD, Bushell D, Davies A, Farogher EB, Miller JP, McCollum CN. von Willebrand factor, the endothelium and obesity. Int J Obes Relat Metab Disord 1993; 17: 723–725.
  23. Blann AD, Jackson P, Bath PM, Watts GF. von Willebrand factor, a possible indicator of endothelial cell damage, decreases during long-term compliance with a lipid-lowering diet. J Intern Med 1995; 237: 557–561.
  24. Blann AD, Mather H, Miller JP, McCollum CN. Atherosclerosis risk factors: variation in healthy hospital workers and members of local communities asymptomatic for vascular disease. Implications for normal controls. Br J Biomed Sci 1995; 52: 31–34.
  25. Blann AD, Maxwell SR, Burrows G, Miller JP. Antioxidants, von Willebrand factor and endothelial cell injury in hypercholesterolemia and vascular disease. Atherosclerosis 1985; 116: 191–198.
  26. Steiner M, Reinhardt KM, Krammer B, Ernst B, Blann AD. Increased levels of soluble adhesion molecules in type II (non-insulin dependent) diabetes mellitus are independent of glycaemic control. Thromb Haemost 1994; 72: 979–984.
  27. Blann AD, McCollum CN. von Willebrand factor, endothelial cell damage and atherosclerosis. Eur J Vasc Surg 1994; 8: 10–15.
  28. Kario K, Hoshide S, Matsuo T, Shimada K. Determinants of endothelial cell damage in the elderly hypertension: Assessment by plasma von Willebrand factor [in Japanese]. Nippon Ronen Igakkai Zasshi 2000; 37: 393–397.
  29. Kario K, Matsuo T, Kobayashi H, Matsuo M, Sakata T, Miyata T, et al. Factor VII hyperactivity and endothelial cell damage are found in elderly hypertensives only when concomitant with microalbuminuria. Arterioscler Thromb Vasc Biol 1996; 16: 455–461.
  30. Lip GY, Edmunds E, Martin SC, Jones AF, Blann AD, Beevers DG. A pilot study of homocysteine levels in essential hypertension: relationship to von Willebrand factor, an index of endothelial damage. Am J Hypertens 2001; 14 ( 7 Pt 1): 627–631.